Evaxion Biotech A/S IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Evaxion Biotech A/S | EVAX - NASDAQ |
$10.00-$12.00 | $10.00 | $10.00 | 3 million | 2/5/2021 |
| Oppenheimer | ||||||
Co-Manager(s): Ladenburg Thalmann | ||||||
| Health Care | ||||||
Filing(s): Filed 2021-01-08 Terms Added 2021-01-25 | ||||||
Evaxion Biotech A/S Quote & Chart - Click for current quote - EVAX
IPO Boutique aggregates information on public companies and private companies, such as "EVAX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Evaxion Biotech A/S (adapted from Evaxion Biotech A/S prospectus):
They are a clinical-stage AI-immunologyâ„¢ platform company using our proprietary artificial intelligence, or AI, technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop novel immunotherapies for the treatment of various cancers, bacterial diseases and viral infections.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage AI-immunologyâ„¢ platform company using our proprietary artificial intelligence, or AI, technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop novel immunotherapies for the treatment of various cancers, bacterial diseases and viral infections.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "EVAX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.